First Camp Lejeune Trial Opens: Mousser Kidney Cancer Case Goes to a Judge, Not a Jury

The first Camp Lejeune trial, Mousser v. United States, opened on Monday, October 26, 2026 in the Eastern District of North Carolina, where Judge Terrence W. Boyle — not a jury — will decide whether contaminated drinking water at the Marine Corps base caused former Marine Frank Mousser's kidney cancer. It is the first time a claim under the Camp Lejeune Justice Act of 2022 has been tried, and it lands four days before the court's October 30 target for a global settlement of an inventory of roughly 408,000 administrative claims and 3,796 filed lawsuits.

The case does not decide anyone else's claim. What it does is put the government's central defense — that trichloroethylene can cause kidney cancer but that ordinary base exposure was too low to cause this one — in front of a federal judge who must write findings of fact. Those findings will be the first judicial read on exposure, diagnosis and causation under the statute's relaxed standard, and every party negotiating the rest of the docket will price off them.

When did the first Camp Lejeune trial start?

The first Camp Lejeune trial started on Monday, October 26, 2026, in federal court in eastern North Carolina, with public radio coverage that morning reporting the case getting underway before Judge Boyle. The trial sits in Elizabeth City, one of the Eastern District's divisional seats, and it is a bench trial: the judge hears the evidence and decides liability and damages himself.

The date moved more than once. In mid-September 2026, Public Radio East reported that Judge Boyle had set Mousser for November 9 and a second kidney cancer case, Fancher, for November 16. A joint status report in early October and coverage after an October 9 status conference placed Mousser on October 26 and Fancher on November 9, and those are the dates that held. Earlier competitor pages that still show November 9 for the first trial are out of date.

The pull-forward matters for one reason above all. It put the opening of the first Camp Lejeune trial inside the same week as the October 30 settlement target, which means both sides walk into the negotiating room with live trial testimony on the record rather than projections about what a judge might find.

Who is the plaintiff in the first Camp Lejeune trial?

The plaintiff is Frank Mousser, a former Marine who was stationed at Camp Lejeune from 1982 to 1986 and who was diagnosed after doctors found a 3.7-centimeter mass on his right kidney in August 2020. According to the Lawsuit Information Center's litigation log, Mousser served in field artillery and alleges that he lived and worked in areas supplied by the Hadnot Point water treatment system, drinking and bathing in water contaminated with industrial solvents including trichloroethylene (TCE). Earlier reporting identified Keller Postman as his counsel.

Mousser is one of 25 Track 1 Trial Plaintiffs selected in July 2024 — five each for kidney cancer, bladder cancer, leukemia, non-Hodgkin lymphoma and Parkinson's disease. Selection came with a cost this newsroom has covered in detail: each Trial Plaintiff waived any claim that an illness outside Track 1 was caused by the water. Mousser is therefore a single-disease case by design. The court wanted a clean test of kidney cancer causation, and that is what it is getting.

His service window is also significant. Hadnot Point was one of the two water systems — alongside Tarawa Terrace — that the Agency for Toxic Substances and Disease Registry (ATSDR) identified as contaminated, and the Camp Lejeune Justice Act covers anyone exposed for at least 30 days between August 1, 1953 and December 31, 1987. A four-year posting from 1982 to 1986 places Mousser well inside the statutory window, and largely before the most contaminated Hadnot Point supply wells were taken out of service in the mid-1980s. That is why the government's argument is not that he was absent or briefly present, but that the dose he received was insufficient.

What does the government argue in the Mousser case?

The government argues that although TCE can cause kidney cancer, the levels of exposure at Camp Lejeune were not sufficient to cause Mousser's cancer, and that his diagnosis is not the type of kidney cancer the science links to TCE. It is not contesting most of his personal history. It is contesting dose and diagnosis.

Three distinct lines of defense have emerged from the pretrial record and the coverage of it.

The dose argument. The Justice Department accepts — as the published science effectively forces it to — that TCE is capable of causing kidney cancer. Its position is that capability is not causation. A substance that causes cancer at occupational exposure levels does not necessarily cause it at the concentrations a Marine would have ingested through base drinking water, and the government argues Mousser cannot show his own dose crossed whatever threshold the science supports.

The diagnosis argument. The government's most technical defense is that Mousser's cancer is upper tract urothelial carcinoma, a cancer of the lining of the renal pelvis or ureter, rather than renal cell carcinoma, the more common cancer of the kidney's functional tissue. The epidemiology tying TCE to "kidney cancer" is strongest for renal cell carcinoma. If the court accepts that the two are different diseases for causation purposes, the plaintiff must prove a link for a cancer type on which the evidence is thinner.

The comparison-study argument. Justice Department lawyers have also relied on a federal cancer-incidence study that did not find a statistically significant increase in kidney cancer among people at Camp Lejeune compared with Marines at Camp Pendleton in California, Public Radio East reported in September. Plaintiffs answer with ATSDR's body of research associating Camp Lejeune contaminants with kidney cancer, and with the statutory text, which does not require statistical significance in any single study.

The diagnosis argument is the one with consequences beyond this courtroom. The government's Elective Option program pays Tier 1 "kidney cancer" claims on a presumption of causation, at between $150,000 and $450,000 depending on exposure duration. A finding that a urothelial cancer in the kidney region is not shown to be caused by the water would hand the government an argument for drawing that tier more narrowly — or for resisting its extension to similar diagnoses in any global deal.

What do Camp Lejeune plaintiffs have to prove at trial?

A Camp Lejeune plaintiff must produce evidence showing that the relationship between exposure to the water at Camp Lejeune and the harm is sufficient to conclude that a causal relationship is at least as likely as not. That is the language of Section 804(c) of the Honoring our PACT Act, and it is the reason the statute exists: Congress wrote a causation standard designed to be easier to meet than ordinary tort law, which in most jurisdictions requires proof that exposure more likely than not caused the injury.

Commentators call this an "equipoise" standard. Section 804 lets a plaintiff satisfy the burden either by showing that a causal relationship is established, or by showing it is at least as likely as not. If the evidence for and against causation is evenly balanced, the plaintiff wins. The first Camp Lejeune trial is the first time a court will apply that standard to a full evidentiary record.

The standard is easier on paper than in practice, for two reasons that the pretrial rulings have made explicit.

First, it does not lower the bar for admissible expert testimony. The court ruled in mid-2026 that the Act's burden of proof does not relax the requirements of Federal Rule of Evidence 702, according to Mealey's and plaintiff-side summaries of the orders. A plaintiff still needs qualified experts using reliable methods to opine on General Causation (can TCE at these levels cause this cancer?) and Specific Causation (did it cause this plaintiff's cancer?). The equipoise standard governs how much weight the judge must find in that evidence once it is admitted; it does not decide what gets admitted. Each side has filed a Daubert Challenge to the other's experts.

Second, the government has pressed throughout for a reading closer to traditional but-for causation. In April 2026 it moved for an early ruling that the Act still requires but-for proof, and the court's June 2026 orders on causation, expert timing and offsets read the standard more demandingly than plaintiffs had sought. Plaintiffs, for their part, are now moving to exclude several of the government's key experts on the ground, as the Lawsuit Information Center put it, that the defense is trying to rewrite the causation standard Congress created.

What the plaintiff therefore has to prove in Mousser, concretely:

• Exposure: at least 30 days at Camp Lejeune in the statutory window, which is not seriously disputed.
• Dose: a reliable estimate of how much contaminated water he consumed and at what concentrations — the point the October 19 motions target.
• General causation: that TCE (and any co-contaminants) at those concentrations can cause his type of cancer — the point the diagnosis argument targets.
• Specific causation: that, for him, it is at least as likely as not that the water caused it, after accounting for other risk factors.
• Damages: the compensable harm, net of statutory offsets.

Why is there no jury in the Camp Lejeune trial?

There is no jury because in February 2024 the four judges of the Eastern District of North Carolina held that the Camp Lejeune Justice Act does not clearly waive the federal government's sovereign immunity from jury trials. Suits against the United States proceed only on the terms Congress sets, and courts presume Congress has not authorized a jury unless it says so unequivocally. The judges found the statute did not.

The ruling turned on a single sentence. Section 804(d) says nothing in the subsection shall impair the right of any party to a trial by jury. Plaintiffs read that as preserving a jury right; the court read it as preserving only whatever jury right otherwise exists — which, against the United States without an express waiver, is none. In May 2024 the court unanimously declined to certify the question for interlocutory appeal, so the Fourth Circuit has never ruled on it.

A bench trial changes the first Camp Lejeune trial in four ways that matter to practitioners:

1. Length. Plaintiffs estimated each Track 1 case could be tried in two to three days; the government estimated about two weeks. A judge who has managed the docket for years does not need the water-modeling and epidemiology record built from scratch.
2. Evidence. Plaintiffs have argued that a judge, unlike a jury, can separate admissible from inadmissible material in ruling on the government's Daubert motions, which reduces the stakes of close evidentiary calls.
3. Findings. Under Federal Rule of Civil Procedure 52, the judge must find the facts specially and state conclusions of law separately. That produces a written explanation of why causation was or was not proved — far more useful to the rest of the docket than a general jury verdict.
4. Range of outcomes. Bench trials compress the variance that produces outlier awards in state-court Mass Tort practice. Combined with the statute's bar on Punitive Damages, that caps the trial's upside at compensatory damages.

The legislative fix — the Ensuring Justice for Camp Lejeune Victims Act (S. 907 and H.R. 4145), which would restore the jury right and allow cases to be heard elsewhere in the Fourth Circuit — has not moved out of committee. Nothing about it affects Mousser.

The October 19 motions: can ATSDR water models prove one Marine's dose?

On October 19, 2026, a week before trial, the Justice Department filed a series of motions challenging the evidence Mousser can use to prove that contaminated water caused his cancer. One targets the historical water contamination models developed by the ATSDR — the government's own public health agency — which reconstruct month-by-month contaminant concentrations at Hadnot Point and Tarawa Terrace across decades for which no direct measurements exist.

The government's position is that the models may be useful for studying exposure across large populations but are not reliable enough to establish how much contaminated water one particular Marine consumed. That is a classic dose-reconstruction argument: a population-level estimate of concentration at a treatment plant is not the same as an individual's intake, which depends on where he lived, worked, showered and ate, and how much he drank.

Plaintiffs' answer, as described in the Lawsuit Information Center's log, is that the government is trying to disqualify the best available reconstruction of what happened precisely because nobody took the measurements that would make reconstruction unnecessary. The contamination at Camp Lejeune ran from the 1950s to the 1980s. The water was not systematically tested for these solvents during most of that period. A rule that only direct measurement can prove individual dose would, in practice, mean that no Camp Lejeune plaintiff could ever prove dose.

The motions also have a history. In December 2025 the judges overseeing the litigation rejected an earlier government bid to block ATSDR evidence, describing the effort as inconsistent given that the government itself had relied on ATSDR's work to connect the water to disease — including in the presumptions behind the Elective Option and VA benefit rules. The October 19 filings narrow the attack from whether the models come in at all to whether they can carry an individual causation opinion. How Judge Boyle handles that distinction will be among the most closely read rulings of the first Camp Lejeune trial, because every remaining claimant relies on the same models.

What is the Camp Lejeune 25-condition census?

The Camp Lejeune 25-condition census is a proposal by the Plaintiffs' Leadership Group, filed in the days before the first trial, asking the court to order every plaintiff's attorney to report which claimants have any of 25 specified diseases and conditions. The proposed order would require counsel to provide each claimant's name, the last four digits of the claimant's Social Security number, the administrative claim number and the diagnosed disease. The group says it needs the data to aid negotiations toward a potential global resolution.

Public Radio East's report lists Parkinson's disease, kidney cancer, bladder cancer, kidney disease and multiple myeloma among the 25. The list is broader than the nine diagnoses currently covered by the government's Elective Option, but it is not a court-approved settlement list and does not guarantee that anyone with a listed condition will be paid. More than 200 individual diseases and conditions have been alleged across the Camp Lejeune claim pool, so even a 25-condition framework would leave a long tail of claims to be handled separately.

Practitioners will recognize the device. A census of this kind is the Camp Lejeune equivalent of a Census Registry in a Multidistrict Litigation (MDL): before anyone can price a global deal, someone has to count how many claimants have each injury. The difference is that Camp Lejeune is not an MDL. The cases were filed in one district because the statute requires it, and the administrative claims sit with the Department of the Navy, not on a court docket. The court has no existing Plaintiff Fact Sheet (PFS) database covering the 400,000-plus administrative claimants, which is why leadership is asking it to compel the count.

The timing is the tell. A census motion filed on the eve of trial, days before a settlement target, signals that the negotiation has moved from "whether" to "how many and at what price per disease." A Settlement Matrix cannot be built without a denominator. The census is an attempt to produce one.

How will the first Camp Lejeune trial affect settlements?

The first Camp Lejeune trial will affect settlements by giving both sides a judicial finding on the questions that drive Claim Value — dose, diagnosis and causation for kidney cancer — at the exact moment they are negotiating a Global Settlement. It will not set a price for other claims, and it will not bind any other court or claimant. Its influence runs through information, not precedent.

Consider what each outcome would signal:

• A plaintiff's judgment with findings that the ATSDR models can support an individual dose estimate would strengthen every claimant who relies on them, which is almost every claimant. It would push the government toward a broader matrix and higher values for Track 1 diseases.
• A defense judgment on the diagnosis ground — that a urothelial cancer is not shown to be caused by the water — would be narrow in reach but would hand the government leverage to split "kidney cancer" into subtypes in any global framework.
• A defense judgment on the dose ground would be the most damaging to the plaintiffs' side, because the dose problem is common to everyone with relatively short or low-concentration exposure.
• A mixed result, such as liability with a modest award after offsets, would anchor values without resolving the bigger questions — a common outcome in a first Bellwether Trial.

Those are the analytical possibilities, not predictions. A judgment may also not arrive quickly. In a bench trial the judge can take the case under advisement and issue written findings later, and if the parties reach a framework in the meantime the decision may matter mostly as a ceiling or floor for holdouts.

There is also the scale problem. As of September 18, 2026, the Justice Department reported more than $1.1 billion in settlement offers and more than $879 million paid, overwhelmingly through the Elective Option. Against roughly 408,000 administrative claims, that is a small fraction of the inventory. Any trial outcome affects the per-claim values in a framework, but the number of claimants who can document both exposure and a qualifying diagnosis will drive the aggregate cost far more than any one judgment. The government's own joint status report has said that more than three-quarters of the claims it has reviewed lack the documentation needed for an Elective Option offer.

Is there a Camp Lejeune global settlement by October 30?

No Camp Lejeune global settlement had been announced as of the opening of the first trial on October 26, 2026. The court has directed the Plaintiffs' Leadership Group and the Justice Department to use their best efforts to reach a global resolution by October 30, 2026, and the parties have been meeting weekly with court-appointed settlement masters.

October 30 is a case management target, not a statutory deadline. No one's claim expires on that date. The court's September 29 order found that progress toward a global settlement was being made and continued the weekly settlement-master sessions; reports differ on whether that order reappointed the plaintiffs' leadership only through October 30 or for a longer term.

Three features of the current posture shape what "a settlement by October 30" could realistically mean:

1. A framework, not a check. The most plausible near-term product is a framework — disease tiers, exposure bands, documentation rules and an administration process — rather than a single aggregate dollar figure. Plaintiff-side trackers have suggested a deal could be proposed during trial, and that partial progress on some diseases is more likely than a full resolution by the target date.
2. Politics. On October 20, President Trump told a Greenville, North Carolina rally that the Justice Department would settle all remaining legitimate claims if Republicans kept control of Congress in the November 3 midterm elections, a pledge that advocates and lawmakers from both parties criticized, as this newsroom reported. The statement does not change the court's schedule, but it adds a political layer to the government's negotiating posture.
3. The census. The Plaintiffs' Leadership Group's 25-condition census motion suggests the parties are still building the claimant count that any matrix requires. A framework announced before that count exists would likely leave the numbers to be filled in later.

What can a judgment in the first Camp Lejeune trial do — and what can't it?

Because this is a single-plaintiff bench trial under a statute with unusual constraints, the range of possible judgments is narrower than in an ordinary product-liability Bellwether Trial.

Question	First Camp Lejeune trial (Mousser)	Typical MDL bellwether
Fact-finder	Judge Terrence W. Boyle (bench trial)	Jury
Causation standard	"At least as likely as not" (Section 804(c))	Usually more likely than not (state law)
Expert admissibility	Rule 702 applies in full	Rule 702 applies in full
Punitive damages	Barred by statute	Often available
Offsets	Mandatory reduction for related VA, Medicare and Medicaid benefits	Collateral-source rules vary by state
Output	Written findings of fact and conclusions of law (Rule 52)	General or special jury verdict
Binding on other claimants	No	No
Appeal	U.S. Court of Appeals for the Fourth Circuit	Circuit of the transferee or trial court
Defendant	United States	Private manufacturer(s)
Interaction with settlement	Runs four days before the October 30 global target	Varies

Two rows deserve emphasis. The offset row means that even a plaintiff's judgment may produce a net award well below the headline damages figure: Section 804 requires any award to be reduced by related disability awards, payments or benefits already provided by the government, including VA disability compensation and Medicare or Medicaid payments. For a long-serving veteran with a high disability rating, the offset can consume a large share of compensatory damages before any Medical Lien or Contingency Fee is deducted. The Justice Department has also taken the position that Federal Tort Claims Act fee caps apply — 20 percent for administrative settlements and 25 percent for suits.

The appeal row matters for timing. Either side can appeal a final judgment to the Fourth Circuit, and given that the case will be the first application of the equipoise standard and the first ruling on individual use of the ATSDR models, an appeal by the losing side is likely. A Fourth Circuit ruling would bind the district on the legal questions for every remaining case — which is one reason a negotiated framework is attractive to both sides before that ruling exists.

What happens after the first Camp Lejeune trial ends?

When the evidence closes, the case does not end with a verdict read in open court. In a bench trial the judge typically takes the matter under advisement, may ask the parties for proposed findings of fact and conclusions of law, and then issues a written decision. There is no fixed deadline for that decision. In a case of this complexity — competing epidemiology, dose reconstruction, a contested diagnosis and statutory offsets — weeks or months between the close of evidence and a written ruling would not be unusual.

Once judgment is entered, the losing party has post-trial options in the district court, including a motion under Rule 52(b) to amend the findings and a motion for a new trial under Rule 59. The deadline to appeal is longer than usual because the United States is a party: under Federal Rule of Appellate Procedure 4(a)(1)(B), either side has 60 days from entry of judgment to file a notice of appeal, rather than the standard 30. A Fourth Circuit decision would then follow on the court's ordinary briefing and argument calendar.

That sequence is one more reason the first Camp Lejeune trial and the settlement talks are running in parallel rather than in series. Waiting for a final, appealed result in Mousser before negotiating would push any global resolution well into 2027 or beyond, for a claimant population that is, in large part, elderly or seriously ill. Both sides gain from the trial's information without needing its finality.

When is the next Camp Lejeune trial?

The next Camp Lejeune trial is Fancher, a second kidney cancer case, set to begin the week of November 9, 2026, also before Judge Boyle as a bench trial. Three more Track 1 trials are slated in total after Mousser, with the next in November, according to the October 26 coverage. The Track 1 leukemia and non-Hodgkin lymphoma cases have been assigned to Judge James C. Dever III.

Date	Event
August 10, 2022	Camp Lejeune Justice Act signed as Section 804 of the Honoring our PACT Act
February 2024	Four E.D.N.C. judges hold there is no jury-trial right against the United States under the Act
July 9, 2024	Order selects 25 Track 1 Trial Plaintiffs across five diseases
August 10, 2024	Two-year window to file administrative claims closes
December 2025	Court rejects government bid to exclude ATSDR evidence
June 2026	Orders on causation standard, Rule 702 and offsets
September 16, 2026	Reported trial settings: Mousser November 9, Fancher November 16
September 18, 2026	DOJ: more than $1.1 billion offered, more than $879 million paid
September 29, 2026	Court finds settlement progress; weekly settlement-master meetings continue
October 2026 (status report / Oct 9 conference)	Mousser moved to October 26; Fancher to November 9
October 19, 2026	DOJ motions challenging ATSDR models and other causation evidence
October 20, 2026	Trump links settling remaining claims to midterm outcome
Days before trial	Plaintiffs' Leadership Group files 25-condition census motion
October 26, 2026	First Camp Lejeune trial, Mousser v. United States, opens
October 30, 2026	Court's target for a global settlement
November 3, 2026	Midterm elections
Week of November 9, 2026	Fancher kidney cancer bench trial

What it means for claimants, counsel, the government and funders

For claimants' counsel. The first Camp Lejeune trial is a reason to audit inventory by diagnosis subtype now. Firms holding "kidney cancer" claims should know which are renal cell carcinoma and which are urothelial or other histologies, because the government has made that distinction the center of its defense and is likely to carry it into any matrix. The same applies to exposure documentation: if the October 19 motions narrow how the ATSDR models can be used for individual dose, claimants with precise housing and duty-station records will be in a materially better position than those relying on a general assertion of presence. Preparing census responses — name, last four Social Security digits, claim number, diagnosis — before any order issues will save time if the court grants the motion.

For claimants weighing an Elective Option offer. The trial does not change the Elective Option grid, which still pays $100,000 to $550,000 depending on tier, exposure duration and whether the claimant died of the condition. It does change the information available for the wait-or-accept decision. A plaintiff's judgment for kidney cancer would tend to support holding out for a framework; a defense judgment on dose or diagnosis would tend to make a fixed administrative offer look better. Elective Option payments are not subject to the same offset rules as court awards, which remains a significant factor in that comparison. This is analysis, not advice; the right answer depends on each claimant's records, health and benefits.

For the Justice Department. The government is defending a statute Congress wrote to make these cases easier to win, in a forum where the judges have already rejected one attempt to exclude its own agency's science. A defense win on dose would be the strongest negotiating outcome available to it; a loss on the ATSDR models would undercut a defense that applies across the entire inventory. The government's diagnosis argument is the most contained risk for it: it can win that point in Mousser without much broader cost.

For litigation funders and lien holders. Third-Party Litigation Funding exposure to Camp Lejeune inventories is priced on assumptions about per-claim value and timing. The first trial will update both. Funders should also note the statutory offsets and the Justice Department's fee-cap position, which reduce what reaches a firm or a claimant from any gross award. VA, Medicare and Medicaid recoveries operate through the offset mechanism for court awards, which is a different route from the conventional Medical Lien negotiation familiar from private Mass Tort settlements.

For mass tort practice generally. The Camp Lejeune docket is the largest single-district toxic exposure litigation against the United States, managed without the Judicial Panel on Multidistrict Litigation (JPML), without juries, and with a statutory causation standard no other Mass Tort uses. If the first Camp Lejeune trial and the October 30 target together produce a framework, it will be an example of a global resolution reached on the strength of bench findings and a court-ordered census rather than jury verdicts — a model with obvious appeal in future federal toxic exposure statutes.

Frequently asked questions

When did the first Camp Lejeune trial start?

The first Camp Lejeune trial, Mousser v. United States, started on Monday, October 26, 2026 in the U.S. District Court for the Eastern District of North Carolina, as a bench trial before Judge Terrence W. Boyle.

Who is the plaintiff in the first Camp Lejeune trial?

The plaintiff is Frank Mousser, a former Marine stationed at Camp Lejeune from 1982 to 1986, who was diagnosed after a 3.7-centimeter mass was found on his right kidney in August 2020. He alleges exposure to TCE-contaminated water from the Hadnot Point system.

Why is there no jury in the Camp Lejeune trial?

The Eastern District of North Carolina held in February 2024 that the Camp Lejeune Justice Act does not clearly waive the United States' sovereign immunity from jury trials, so all Camp Lejeune cases are tried to a judge. The court declined to certify the question for appeal, and a bill to restore jury trials has not advanced.

What does the government argue in the Mousser case?

The government concedes that TCE can cause kidney cancer but argues that Mousser's exposure was too low to cause his, that his cancer is upper tract urothelial carcinoma rather than renal cell carcinoma, and that the ATSDR water models cannot establish one person's dose.

What is the Camp Lejeune 25-condition census?

It is a Plaintiffs' Leadership Group motion asking the court to require attorneys to report each claimant with any of 25 listed conditions — including Parkinson's disease, kidney cancer, bladder cancer, kidney disease and multiple myeloma — by name, last four Social Security digits, claim number and diagnosis, to support global settlement talks. It is not a settlement list.

Is there a Camp Lejeune global settlement by October 30?

No global settlement had been announced when the first trial opened on October 26, 2026. The court has asked the parties to use their best efforts to reach one by October 30, 2026; the date is a court target, not a deadline that ends anyone's claim.